{"title":"儿童化疗所致耳毒性的评估与处理。","authors":"Heonjeong Oh, Moo Kyun Park","doi":"10.7874/jao.2025.00073","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy-induced ototoxicity is a significant concern in pediatric patients with cancer, particularly those treated with platinum-based agents, such as cisplatin and carboplatin. This study reviewed its prevalence, risk factors, early diagnosis, and management strategies. A literature review was conducted to assess the effects of ototoxic chemotherapy, screening methods, and treatment approaches. Various grading scales and rehabilitation strategies were analyzed. Platinum-based chemotherapy causes ototoxic hearing loss in approximately 100% of cases, including high-frequency and delayed-onset losses. Younger age, higher cumulative dose, and cranial irradiation increased the risk. Screening adherence remains suboptimal, despite guidelines recommending early detection through high-frequency audiometry. Sodium thiosulfate may reduce ototoxicity in nonmetastatic cases. If appropriate, hearing aids and cochlear implants can support communication and language development. Ototoxic hearing loss is a prevalent, yet underdiagnosed, complication of pediatric cancer treatment. Standardized screening, otoprotective strategies, and early rehabilitation are essential to minimize their impact on language and quality of life. Greater awareness and national guidelines are required to improve the care of pediatric cancer survivors.</p>","PeriodicalId":44886,"journal":{"name":"Journal of Audiology and Otology","volume":"29 2","pages":"79-85"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046201/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment and Management of Chemotherapy-Induced Ototoxicity in Children.\",\"authors\":\"Heonjeong Oh, Moo Kyun Park\",\"doi\":\"10.7874/jao.2025.00073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chemotherapy-induced ototoxicity is a significant concern in pediatric patients with cancer, particularly those treated with platinum-based agents, such as cisplatin and carboplatin. This study reviewed its prevalence, risk factors, early diagnosis, and management strategies. A literature review was conducted to assess the effects of ototoxic chemotherapy, screening methods, and treatment approaches. Various grading scales and rehabilitation strategies were analyzed. Platinum-based chemotherapy causes ototoxic hearing loss in approximately 100% of cases, including high-frequency and delayed-onset losses. Younger age, higher cumulative dose, and cranial irradiation increased the risk. Screening adherence remains suboptimal, despite guidelines recommending early detection through high-frequency audiometry. Sodium thiosulfate may reduce ototoxicity in nonmetastatic cases. If appropriate, hearing aids and cochlear implants can support communication and language development. Ototoxic hearing loss is a prevalent, yet underdiagnosed, complication of pediatric cancer treatment. Standardized screening, otoprotective strategies, and early rehabilitation are essential to minimize their impact on language and quality of life. Greater awareness and national guidelines are required to improve the care of pediatric cancer survivors.</p>\",\"PeriodicalId\":44886,\"journal\":{\"name\":\"Journal of Audiology and Otology\",\"volume\":\"29 2\",\"pages\":\"79-85\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046201/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Audiology and Otology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7874/jao.2025.00073\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Audiology and Otology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7874/jao.2025.00073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Assessment and Management of Chemotherapy-Induced Ototoxicity in Children.
Chemotherapy-induced ototoxicity is a significant concern in pediatric patients with cancer, particularly those treated with platinum-based agents, such as cisplatin and carboplatin. This study reviewed its prevalence, risk factors, early diagnosis, and management strategies. A literature review was conducted to assess the effects of ototoxic chemotherapy, screening methods, and treatment approaches. Various grading scales and rehabilitation strategies were analyzed. Platinum-based chemotherapy causes ototoxic hearing loss in approximately 100% of cases, including high-frequency and delayed-onset losses. Younger age, higher cumulative dose, and cranial irradiation increased the risk. Screening adherence remains suboptimal, despite guidelines recommending early detection through high-frequency audiometry. Sodium thiosulfate may reduce ototoxicity in nonmetastatic cases. If appropriate, hearing aids and cochlear implants can support communication and language development. Ototoxic hearing loss is a prevalent, yet underdiagnosed, complication of pediatric cancer treatment. Standardized screening, otoprotective strategies, and early rehabilitation are essential to minimize their impact on language and quality of life. Greater awareness and national guidelines are required to improve the care of pediatric cancer survivors.
期刊介绍:
Journal of Audiology and Otology (JAO) (formerly known as Korean Journal of Audiology) aims to publish the most advanced findings for all aspects of the auditory and vestibular system and diseases of the ear using state-of-the-art techniques and analyses. The journal covers recent trends related to the topics of audiology, otology, and neurotology conducted by professionals, with the goal of providing better possible treatment to people of all ages, from infants to the elderly, who suffer from auditory and/or vestibular disorders and thus, improving their quality of life. This journal encourages the submission of review papers about current professional issues, research papers presenting a scientific base and clinical application, and case papers with unique reports or clinical trials. We also invite letters to the editor and papers related to the manufacture and distribution of medical devices. This journal provides integrated views from otologists, audiologists, and other healthcare practitioners, offering readers high quality scientific and clinical information. This peer-reviewed and open access journal has been the official journal of the Korean Audiological Society since 1997 and of both the Korean Audiological Society and the Korean Otological Society since 2017. It is published in English four times a year in January, April, July, and October.